Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$160.99 - $215.69 $464,134 - $621,834
-2,883 Reduced 64.07%
1,617 $308,000
Q3 2023

Nov 14, 2023

SELL
$194.33 - $283.97 $20.6 Million - $30.2 Million
-106,245 Reduced 95.94%
4,500 $895,000
Q2 2023

Aug 14, 2023

BUY
$223.05 - $302.68 $13.6 Million - $18.4 Million
60,846 Added 121.94%
110,745 $31.6 Million
Q1 2023

May 15, 2023

SELL
$175.41 - $217.92 $11.2 Million - $13.9 Million
-63,841 Reduced 56.13%
49,899 $10.8 Million
Q4 2022

Feb 14, 2023

BUY
$204.38 - $296.82 $5.18 Million - $7.52 Million
25,335 Added 28.66%
113,740 $23.4 Million
Q3 2022

Nov 14, 2022

BUY
$195.21 - $310.53 $17.3 Million - $27.5 Million
88,405 New
88,405 $24.6 Million
Q2 2022

Aug 15, 2022

SELL
$115.91 - $214.48 $4.55 Million - $8.42 Million
-39,242 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$127.96 - $207.36 $8.07 Million - $13.1 Million
-63,050 Reduced 61.64%
39,242 $8.14 Million
Q4 2021

Feb 14, 2022

SELL
$165.13 - $241.83 $8.55 Million - $12.5 Million
-51,799 Reduced 33.62%
102,292 $18.2 Million
Q3 2021

Nov 15, 2021

SELL
$163.99 - $235.57 $8.28 Million - $11.9 Million
-50,498 Reduced 24.68%
154,091 $31.7 Million
Q2 2021

Aug 16, 2021

SELL
$131.45 - $201.49 $169,307 - $259,519
-1,288 Reduced 0.63%
204,589 $38.8 Million
Q1 2021

May 17, 2021

SELL
$92.73 - $142.05 $5.72 Million - $8.76 Million
-61,678 Reduced 23.05%
205,877 $26.8 Million
Q4 2020

Feb 16, 2021

SELL
$67.44 - $103.72 $767,467 - $1.18 Million
-11,380 Reduced 4.08%
267,555 $27.8 Million
Q3 2020

Nov 16, 2020

BUY
$42.79 - $75.8 $10.2 Million - $18 Million
238,050 Added 582.24%
278,935 $21.1 Million
Q2 2020

Aug 14, 2020

BUY
$27.25 - $47.53 $1.11 Million - $1.94 Million
40,885 New
40,885 $1.94 Million

Others Institutions Holding SWAV

About Shockwave Medical, Inc.


  • Ticker SWAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,927,100
  • Description
  • ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease ...
More about SWAV
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.